Tissue engineering's green shoots of disruptive innovation. (2014)
Attributed to:
RegenVOX: phase I/II clinical trial of stem cell based tissue engineered laryngeal implants
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(14)60533-x
PubMed Identifier: 24726476
Publication URI: http://europepmc.org/abstract/MED/24726476
Type: Journal Article/Review
Volume: 384
Parent Publication: Lancet (London, England)
Issue: 9940
ISSN: 0140-6736